Hepatobiliary-specific MR contrast agents: Role in imaging the liver and biliary tree

Radiographics

Volumn 29, Issue 6, 2009, Pages 1725-1748

  Seale, Melanie K ^a   Catalano, Onofrio A ^a   Saini, Sanjay ^a   Hahn, Peter F ^a   Sahani, Dushyant V ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONTRAST MEDIUM; DIAGNOSTIC AGENT; DRUG DERIVATIVE; EDETIC ACID; GADOBENIC ACID; GADOLINIUM ETHOXYBENZYL DTPA; GADOLINIUM PENTETATE; MEGLUMINE; N,N' BIS(PYRIDOXAL 5 PHOSPHATE)ETHYLENEDIAMINE N,N' DIACETIC ACID; N,N'-BIS(PYRIDOXAL-5-PHOSPHATE)ETHYLENEDIAMINE-N,N'-DIACETIC ACID; ORGANOMETALLIC COMPOUND; PYRIDOXAL 5 PHOSPHATE;

ARTICLE; BILE DUCT; HUMAN; IMAGE ENHANCEMENT; LIVER; LIVER DISEASE; METHODOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY;

BILE DUCTS; CONTRAST MEDIA; EDETIC ACID; GADOLINIUM DTPA; HUMANS; IMAGE ENHANCEMENT; LIVER; LIVER DISEASES; MAGNETIC RESONANCE IMAGING; MEGLUMINE; ORGANOMETALLIC COMPOUNDS; PYRIDOXAL PHOSPHATE;

EID: 77449106886     PISSN: 02715333     EISSN: 15271323     Source Type: Journal    
DOI: 10.1148/rg.296095515     Document Type: Article

References (50)

1. Gandhi SN, Brown MA, Wong JG, Aguirre DA, Sirlin CB. MR contrast agents for liver imaging: what, when, how. RadioGraphics 2006;26:1621-1636.
2. Edelman RR, Siegel JB, Singer A, Dupuis K, Longmaid HE. Dynamic MR imaging of the liver with Gd-DTPA: initial clinical results. AJR Am J Roentgenol 1989;153:1213-1219.
3. Semelka RC, Helmberger TKG. Contrast agents for MR imaging of the liver. Radiology 2001;218: 27-38.
4. Wertman R, Altun E, Martin DR, et al. Risk of nephrogenic systemic fibrosis: evaluation of gadolinium chelate contrast agents at four American universities. Radiology 2008;248:799-806.
5. Grazioli L, Morana G, Federle MP, et al. Focal nodular hyperplasia: morphologic and functional information from MR imaging with gadobenate dimeglumine. Radiology 2001;221:731-739.
6. Tajima T, Honda H, Taguchi K, et al. Sequential hemodynamic change in hepatocellular carcinoma and dysplastic nodules: CT angiography and pathologic correlation. AJR Am J Roentgenol 2002; 178:885-897.
7. Reimer P, Schneider G, Schima W. Hepatobiliary contrast agents for contrast-enhanced MRI of the liver: properties, clinical development and applications. Eur Radiol 2004;14:559-578.
8. Kirchin MA, Pirovano G, Venetianer C, Spinazzi A. Safety assessment of gadobenate dimeglumine (MultiHance): extended clinical experience from phase I studies to post-marketing surveillance. J Magn Reson Imaging 2001;14:281-294.
9. Wang C, Ahlström H, Eriksson B, Lönnemark M, McGill S, Hemmingsson A. Uptake of mangafodipir trisodium in liver metastases from endocrine tumors. J Magn Reson Imaging 1998;8:682-686.
10. Maravilla KR. Gadobenate dimeglumine-enhanced MR imaging of patients with CNS diseases. Eur Radiol 2006;16(suppl 7):M8-M15.
11. Kuwatsuru R, Kadoya M, Ohtomo K, et al. Comparison of gadobenate dimeglumine with gadopentetate dimeglumine for magnetic resonance imaging of liver tumors. Invest Radiol 2001;36: 632-641.
12. Hughes K, Scheele J, Sugarbaker PH. Surgery for colorectal cancer metastatic to the liver: optimizing the results of treatment. Surg Clin North Am 1989;69:339-359.
13. Fusai G, Davidson BR. Management of colorectal liver metastases. Colorectal Dis 2003;5:2-23.
14. Cantwell CP, Setty BN, Holalkere N, Sahani DV, Fischman AJ, Blake MA. Liver lesion detection and characterization in patients with colorectal cancer: a comparison of low radiation dose non-enhanced PET/CT, contrast-enhanced PET/CT, and liver MRI. J Comput Assist Tomogr 2008;32:738-744.
15. Bipat S, van Leeuwen MS, Comans EFI, et al. Colorectal liver metastases: CT, MR imaging, and PET for diagnosis-meta-analysis. Radiology 2005; 237:123-131.
16. Schneider G, Maas R, Schultze Kool L, et al. Lowdose gadobenate dimeglumine versus standard dose gadopentetate dimeglumine for contrastenhanced magnetic resonance imaging of the liver: an intra-individual crossover comparison. Invest Radiol 2003;38:85-94.
17. Petersein J, Spinazzi A, Giovagnoni A, et al. Focal liver lesions: evaluation of the efficacy of gadobenate dimeglumine in MR imaging-a multicenter phase III clinical study. Radiology 2000;215:727736.
18. Sahani DV, Kalva SP, Fischman AJ, et al. Detection of liver metastases from adenocarcinoma of the colon and pancreas: comparison of mangafodipir trisodium-enhanced liver MRI and wholebody FDG PET. AJR Am J Roentgenol 2005;185: 239-246.
19. Bajpai S, Sahani DV. Recent progress in imaging of colorectal cancer liver metastases. Curr Colorectal Cancer Rep 2009;5:99-107.
20. Kim HJ, Kim KW, Byun JH, et al. Comparison of mangafodipir trisodium and ferucarbotranenhanced MRI for detection and characterization of hepatic metastases in colorectal cancer patients. AJR Am J Roentgenol 2006;186:1059-1066.
21. Bartolozzi C, Donati F, Cioni D, et al. Detection of colorectal liver metastases: a prospective multicenter trial comparing unenhanced MRI, MnDPDP-enhanced MRI, and spiral CT. Eur Radiol 2004;14:14-20.
22. Del Frate C, Bazzocchi M, Mortele KJ, et al. Detection of liver metastases: comparison of gadobenate dimeglumine-enhanced and ferumoxidesenhanced MR imaging examinations. Radiology 2002;225:766-772.
23. Kim YK, Lee JM, Kim CS, Chung GH, Kim CY, Kim IH. Detection of liver metastases: gadobenate dimeglumine-enhanced three-dimensional dynamic phases and one-hour delayed phase MR imaging versus superparamagnetic iron oxide-enhanced MR imaging. Eur Radiol 2005;15:220-228.
24. Zech CJ, Herrman KA, Reiser MF, Schoenberg SO. MR imaging in patients with suspected liver metastases: value of liver-specific contrast agent Gd-EOB-DTPA. Magn Reson Med Sci 2007;6: 43-52.
25. Hammerstingl R, Huppertz A, Breuer J, et al. Diagnostic efficacy of gadoxetic acid (Primovist)enhanced MRI and spiral CT for a therapeutic strategy: comparison with intraoperative and histopathologic findings in focal liver lesions. Eur Radiol 2008;18:457-467.
26. Huppertz A, Haraida S, Kraus A, et al. Enhancement of focal liver lesions at gadoxetic acid-enhanced MR imaging: correlation with histopathologic findings and spiral CT-initial observations. Radiology 2005;234:468-478.
27. Siegelman ES. Body MR techniques and MR of the liver. In: Siegelman ES, ed. Body MRI. Philadelphia, Pa: Elsevier Saunders, 2005; 1-63.
28. Grazioli L, Morana G, Kirchin MA, Schneider G. Accurate differentiation of focal nodular hyperplasia from hepatic adenoma at gadobenate dimeglumine-enhanced MR imaging: prospective study. Radiology 2005;236:166-177.
29. Scharitzer M, Schima W, Schober E, et al. Characterization of hepatocellular tumors: value of mangafodipir-enhanced magnetic resonance imaging. J Comput Assist Tomogr 2005;29:181-190.
30. Savellano DH, Köstler H, Baus S, et al. Assessment of sequential enhancement patterns of focal nodular hyperplasia and hepatocellular carcinoma on mangafodipir trisodium enhanced MR imaging. Invest Radiol 2004;39:305-312.
31. Charny CK, Jarnagin WR, Schwartz LH, et al. Management of 155 patients with benign liver tumours. Br J Surg 2001;88:808-813.
32. Grazioli L, Federle MP, Brancatelli G, Ichikawa T, Olivetti L, Blachar A. Hepatic adenomas: imaging and pathologic findings. RadioGraphics 2001; 21:877-892.
33. Sahani DV, O'Malley ME, Bhat S, Hahn PF, Saini S. Contrast-enhanced MRI of the liver with mangafodipir trisodium: imaging technique and results. J Comput Assist Tomogr 2002;26:216-222.
34. King LJ, Burkill GJ, Scurr ED, Vlavianos P, Murray-Lyons I, Healy JC. MnDPDP enhanced magnetic resonance imaging of focal liver lesions. Clin Radiol 2002;57:1047-1057.
35. Huppertz A, Balzer T, Blakeborough A, et al. Improved detection of focal liver lesions at MR imaging: multicenter comparison of gadoxetic acidenhanced MR images with intraoperative findings. Radiology 2004;230:266-275.
36. Willatt JM, Hussain HK, Adusumilli S, Marrero JA. MR imaging of hepatocellular carcinoma in the cirrhotic liver: challenges and controversies. Radiology 2008;247:311-330.
37. Colli A, Fraquelli M, Casazza G, et al. Accuracy of ultrasonography, spiral CT, magnetic resonance and alpha-fetoprotein in diagnosing hepatocellular carcinoma: a systematic review. Am J Gastroenterol 2006;101:513-523.
38. Bartolozzi C, Donati F, Cioni D, Crocetti L, Lencioni R. MnDPDP-enhanced MRI vs dual-phase spiral CT in the detection of hepatocellular carcinoma in cirrhosis. Eur Radiol 2000;10:1697-1702.
39. Choi SH, Lee JM, Yu NC, et al. Hepatocellular carcinoma in liver transplantation candidates: detection with gadobenate dimeglumine-enhanced MRI. AJR Am J Roentgenol 2008;191:529-536.
40. Hanna RF, Aguirre DA, Kased N, Emery SC, Peterson MR, Sirlin CB. Cirrhosis-associated hepatocellular nodules: correlation of histopathologic and MR imaging features. RadioGraphics 2008; 28:747-769.
41. Digumarthy SR, Sahani DV, Saini S. MRI in detection of hepatocellular carcinoma (HCC). Cancer Imaging 2005;5:20-24.
42. Sahani D, Mehta A, Blake M, Prasad S, Harris G, Saini S. Preoperative hepatic vascular evaluation with CT and MR angiography: implications for surgery. RadioGraphics 2004;24:1367-1380.
43. Catalano OA, Singh AH, Uppot RN, Hahn PF, Ferrone CR, Sahani DV. Vascular and biliary variants in the liver: implications for liver surgery. RadioGraphics 2008;28:359-378.
44. Sahani D, D'Souza R, Kadavigere R, et al. Evaluation of living liver transplant donors: method for precise anatomic definition by using a dedicated contrast-enhanced MR imaging protocol. RadioGraphics 2004;24:957-967.
45. Fayad LM, Holland GA, Bergin D, et al. Functional magnetic resonance cholangiography (fMRC) of the gallbladder and biliary tree with contrast-enhanced magnetic resonance cholangiography. J Magn Reson Imaging 2003;18:449-460.
46. Hoeffel C, Azizi L, Lewin M, et al. Normal and pathologic features of the postoperative biliary tract at 3D MR cholangiopancreatography and MR imaging. RadioGraphics 2006;26:1603-1620.
47. Fink-Bennett D. Hepatobiliary imaging. In: Henkin RE, ed. Nuclear medicine. 2nd ed. Philadelphia, Pa: Mosby Elsevier, 2006; 968-987.
48. Dahlstrom N, Persson A, Albiin N, Smedby O, Brismar TB. Contrast-enhanced magnetic resonance cholangiography with Gd-BOPTA and GdEOB-DTPA in healthy subjects. Acta Radiol 2007; 48:362-368.
49. Tsuda N, Okada M, Murakami T. Potential of gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid (Gd-EOB-DTPA) for differential diagnosis of nonalcoholic steatohepatitis and fatty liver in rats using magnetic resonance imaging. Invest Radiol 2007;42:242-247.
50. Tsuda N, Okada M, Murakami T. New proposal for the staging of nonalcoholic steatohepatitis: evaluation of liver fibrosis on Gd-EOB-DTPAenhanced MRI. Eur J Radiol doi:10.1016/j.ejrad /2008.09.036. Published online November 20, 2008. Accessed February 18, 2009.